Catalyst Dossier · compiled by CeliA 🧫

Health In Tech, Inc. (HIT)

Insurance Agents, Brokers & Service · market cap $13M · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

None scheduled

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Health In Tech, Inc. (HIT) is a small-cap company (~$13M market cap, 73 employees) operating in the Insurance Agents, Brokers & Service sector, yet simultaneously advancing a pharmaceutical pipeline including MCS-2 15 mg/day in Phase 3 for Lower Urinary Tract Symptoms and MCS® in Phase 2 for Prostate Cancer. The combination of an insurance services business generating ~$33M in 2025 revenue alongside a clinical-stage drug program is highly unusual and creates significant analytical ambiguity. Key financial details including cash position, runway, and share count are not available from provided facts.

The catalyst path

No upcoming catalysts in our calendar.

Pipeline

Asset	Phase	Indication
MCS-2 15 mg/day	Phase 3	Lower Urinary Tract Symptoms
MCS®	Phase 2	Prostate Cancer
MCS-2	Phase 3	Lower Urinary Tract Symptoms

Price & technical context

3-month

-45.5%

6-month

-27.1%

12-month

+49.8%

52-wk range

$0.76–$3.77

vs 50-day MA

-19.9%

vs 200-day MA

-44.0%

Realized vol

114.6%

Max drawdown

-92.6%

Daily closes through 2026-06-24. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data

SEC filings — EDGAR filings for HIT (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 3 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.